In short. Every component carries its own approval and its own indication, and a sequence is a clinical plan rather than a regulated entity. What that means in practice.
Key points
- Approval and evidence are separate questions throughout this cluster.
- A sequence can rest on sound principles and carry no approval whatever.
- What it cannot do is borrow an approval from one of its components and present that as covering the plan, which is the most common way the two are conflated.
Regulation in this field works component by component, and a sequence has no regulatory status at all. That is not a gap in the rules; it follows from what a sequence is.
What each component carries
An injectable substance is approved as a product for a defined use in a defined market. A device is approved for a defined indication, and that approval belongs to the device rather than to the family it sits in. A topical is regulated as a cosmetic or as a medicine depending on the claims made for it, and the line between those two is drawn differently in different markets. Each of those approvals is narrow, specific and granted separately.
Why a sequence cannot be approved
A sequence is not a product, an indication or a claim that a regulator can review. It is a plan drawn up over time for one person, revised as each step is judged. There is nothing to label, nothing to clear and nothing to recall, which is why the structure of regulation has no slot for it. The absence of approval is therefore not a comment on whether sequencing works; it is a statement that the thing being described is not the kind of thing approval applies to.
No approval is not the same as no evidence
Approval and evidence are separate questions throughout this cluster. A sequence can rest on sound principles and carry no approval whatever. What it cannot do is borrow an approval from one of its components and present that as covering the plan, which is the most common way the two are conflated.
Where the responsibility sits
Because nothing reviews the sequence, the reasoning and the responsibility belong to the clinician who made it. Two things follow for a reader. The explanation behind a programme is not a courtesy; it is the only accountability the programme has, and it is reasonable to expect it in words. And a page that describes a sequence as approved, cleared or established as a standard of care has moved from a fact about a product to a claim about a plan without saying so.
Approval claims that do not hold
- A component approval presented as covering the sequence as a whole.
- An interval described as required by a regulator when it is a clinical judgement.
- A clearance in one market described as though it applied to the programme everywhere.
Reported separately, approval and evidence are both useful. Merged into a single sentence, they are neither.
Frequently asked questions
Is a sequence of treatments approved by a regulator?
No. Regulators approve products, devices and indications. A sequence of several treatments over time is not one of those, so it has no approval at all. The sequence is a clinical plan made for one person, and its justification is the reasoning behind it rather than a clearance.
Are the intervals between treatments regulated?
No. The interval is a clinical judgement about healing, and while there is a principled basis for choosing it, no regulator fixes it. That is why an interval should be explained in terms of what was done and what the tissue needs rather than presented as a protocol requirement that has been met.
What is each component approved for?
Its own indication, in its own market. An injectable is approved as a product for a defined use, a device for a defined indication, a topical as a cosmetic or a medicine depending on its claims. None of those approvals extends to the plan, and a page implying otherwise has described a product as though it were a programme.
Risks & Limitations
- Sequencing separates treatments in time, which is not the same as combining them in one episode; the two are different strategies.
- Each component is approved on its own indication, and no regulator approves a sequence or fixes the interval between treatments.
- That a preferred order changes the outcome, and that more modalities produce more, are not established by the evidence.
- A sequence is a plan with a direction rather than a schedule, and its advantage is lost if the plan cannot change.
- A sequence lowers the burden on the tissue at any one moment; it does not lower the total, and the healing time adds up.
When to Seek Care
- Increasing pain, spreading redness or warmth, or a fever after any treatment — have it assessed urgently.
- Blistering, crusting or an open area that does not settle after a device treatment — have it assessed by a clinician.
- Pigment that darkens or spreads beyond the treated area over the following weeks — have it assessed by a clinician.
- A change in vision, speech or skin colour after an injectable — seek emergency care immediately.
References & Further Reading
- U.S. Food and Drug Administration (FDA) — approved products, devices and their labelled indications
- National Medical Products Administration (NMPA, China) — approved products and their indications
- National Institute for Health and Care Excellence (NICE, UK) — relevant guidance
- Cochrane Library — systematic reviews of laser, light and injectable treatment
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is a review of published evidence and regulation, not medical advice, and it does not cite individual studies. It is not a booking page and it does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.